Associate Professor Helen Cox BSc MPH PhD (Melbourne)
Wellcome Trust Intermediate Fellow in Public Health and Tropical Medicine; Senior Researcher, Medical Microbiology, University of Cape Town; Member of the Institute of Infectious Disease and Molecular (IDM), Faculty of Health Sciences, University of Cape Town; Adjunct Senior Lecturer, Monash University, Melbourne, Australia. Winner of the 2015 Union Scientific Prize, International Union Against Tuberculosis and Lung Disease.
Helen Cox is an epidemiologist specialising in drug resistant tuberculosis, with expertise in TB diagnostics and treatment. Specific research interests include: the molecular epidemiology of drug-resistant TB, models of care and optimising treatment regimens for drug-resistant TB, co-treatment of HIV with antiretroviral drugs, rapid diagnostics for tuberculosis drug resistance and developing sustainable interventions to improve TB infection control in health care facilities.
Current projects include:
- A systems approach to evaluating prospects for the control of drug-resistant tuberculosis in Khayelitsha, South Africa.
- Feasibility and impact of GeneXpert for TB and drug-resistant TB diagnosis.
- Outcomes of decentralised programmatic management of drug-resistant TB in Khayelitsha.
- Molecular epidemiology of drug-resistant TB in Central Asia and South Africa.
- Linkage to care among patients diagnosed with rifampicin-resistant TB across South Africa.
Furin J, Cox H. Outbreak of multidrug-resistant tuberculosis on Daru Island. The Lancet Respiratory Medicine (2016) 4(5):347-349.
Van Cutsem G, Isaakidis P, Farley J, Nardell E, Volchenkov G, Cox H. Infection control for drug-resistant tuberculosis: early diagnosis and treatment is the key. Clinical Infectious Diseases (2016) 62:S238-S243.
London L, Cox H, Coomans F. Multidrug-resistant TB: implementing the right to health through the right to enjoy the benefits of scientific progress. Health and Human Rights (2016) 18(1):25-41.
Cox HS, Furin JJ, Mitnick CD, Daniels C, Cox V, Goemaere E. The need to accelerate access to new drugs for multidrug-resistant tuberculosis. Bull World Health Organ. (2015) 93(7):491-7.
Cox H, Ramma L, Wilkinson L, Azevedo V, Sinanovic E. Cost per patient of treatment for rifampicin-resistant tuberculosis in a community-based programme in Khayelitsha, South Africa. Trop Med Int Health. (2015)
Cox H, Mbhele S, Mohess N, Whitelaw A, Muller O, Zemanay W, et al. Impact of Xpert MTB/RIF implementation for TB diagnosis in a high TB and HIV prevalence primary care clinic in South Africa: a pragmatic randomised trial. PLoS Med. (2014) 11(11):e1001760.
Cox H, Hughes J, Daniels J, Azevedo V, McDermid C, Poolman M, et al. Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa. Int J Tuberc Lung Dis. (2014) 18(4):441-8.
Division of Medical Microbiology
Department of Pathology
Room 5.24, Falmouth Building
Institute of Infectious Disease and Molecular Medicine
UCT Faculty of Health Sciences
Tel: +27 21 406 6378
Cell: +27 76 716 9702
Fax: +27 21 406 6068
External site: www.medmicro.uct.ac.za
- Molecular epidemiology of drug-resistant TB in Khayelitsha: Prof Robin Warren, Division of Molecular Biology and Human Genetics, Faculty of Health Sciences, Stellenbosch University, South Africa
- Molecular epidemiology of drug-resistant TB in Karakalpakstan, Uzbekistan: Prof Stefan Niemann, Molecular Mycobacteriology, Research Centre Borstel, Germany
- Evaluation of decentralised drug-resistant care in Khayelitsha: Médecins Sans Frontières, South Africa
- Linkage to care among patients diagnosed with rifampicin-resistant TB across South Africa: Prof Mark Nicol, Division of Medical Microbiology and Institute of Infectious Disease and Molecular Medicine, University of Cape Town